



May 25, 2021

To: Alberta Securities Commission
British Columbia Securities Commission
Ontario Securities Commission

We have read the statements made by BioMark Diagnostic Inc. in the attached copy of change of auditor notice dated May 17, 2021, which we understand will be filed pursuant to Section 4.11 of National Instrument 51-102.

We agree with the statements concerning PricewaterhouseCoopers LLP in the change of auditor notice dated May 17, 2021.

Yours very truly,

PricewaterhouseCoopers LLP

Partnership of Chartered Professional Accountants



NOTICE OF CHANGE OF AUDITORS PURSUANT TO
NATIONAL INSTRUMENT 51-102

To: Alberta Securities Commission
British Columbia Securities Commission
Ontario Securities Commission

And To: Manning Elliott LLP
PricewaterhouseCoopers LLP

Re: Notice Regarding Change of Auditor Pursuant to National Instrument 51-102

Notice is hereby given that at the request of BioMark Diagnostics Inc. (the "Company" or "BioMark"), Manning Elliott LLP (the "Former Auditor") resigned as auditors of the Company effective May 17, 2021 and PricewaterhouseCoopers LLP has been appointed as auditors of the Company effective May 17, 2021. The Audit Committee and the Board of Directors of BioMark considered and approved both the resignation of the Former Auditor and the appointment of PricewaterhouseCoopers LLP as auditor of BioMark.

There have been no reservations in the Former Auditor's Report on any of the Company's financial statements commencing at the beginning of the two most recently completed fiscal years and ending on March 31, 2020. The Former Auditor did not audit any financial statements of the Company subsequent to the March 31, 2020 fiscal year of the Company.

In the opinion of the Company, prior to the resignation, and as at the date hereof, there were no reportable events, including disagreements, consultations, or unresolved issues as defined in National Instrument 51-102, Continuous Disclosure Obligations, between the Former Auditor and the Company.

The contents of this Notice and the attached letters from PricewaterhouseCoopers LLP and Manning Elliott LLP have been reviewed by the Board of Directors.

DATED at Richmond, British Columbia this 17th day of May 2021.

BY ORDER OF THE BOARD OF DIRECTORS OF
BIOMARK DIAGNOSTICS INC.

Signed "Guoyu Huang"

Guoyu Huang
Chief Financial Officer